Sandhia S. Ponnarambil

BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Journal: International forum of allergy & rhinology

Published: July 22, 2026

Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.

Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: May 13, 2026

Reply to: S. N. Katkuri et al. and H. Liu et al. on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Reply to: S. N. Katkuri et al. and H. Liu et al. on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Journal: International forum of allergy & rhinology

Published: April 02, 2026

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: December 22, 2025

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Journal: International forum of allergy & rhinology

Published: September 05, 2025

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.

Journal: The New England journal of medicine

Published: March 19, 2025

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 13, 2025

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.

Journal: Pulmonary therapy

Published: December 18, 2024

Clarification of the efficacy of tezepelumab in the phase 2a COURSE trial.

Clarification of the efficacy of tezepelumab in the phase 2a COURSE trial.

Journal: The Journal of allergy and clinical immunology

Published: December 03, 2024

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.

Journal: The Journal of allergy and clinical immunology

Published: July 17, 2024

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.

Journal: The Lancet. Respiratory medicine

Published: June 04, 2024

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.

Journal: ERJ open research

Published: February 19, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026